Icecure Medical Ltd (ICCM)

Currency in USD
0.832
-0.008(-0.95%)
Real-time Data·
ICCM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ICCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.7800.865
52 wk Range
0.4801.660
Key Statistics
Prev. Close
0.84
Open
0.81
Day's Range
0.78-0.865
52 wk Range
0.48-1.66
Volume
158.27K
Average Volume (3m)
1.08M
1-Year Change
36.81%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.010
Upside
+261.78%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Icecure Medical Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Icecure Medical Ltd Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Icecure Medical Ltd Earnings Call Summary for Q4/2024

  • Product sales up 8% to $3.19M, total revenue $3.29M; net loss widened to $15.32M ($0.30/share)
  • Gross profit improved 12%, margin up from 40% to 44%; stock price fell 5.26% post-earnings
  • North American sales grew 42%; awaiting FDA decision on ProSense system
  • CEO optimistic about sales growth and cost management; anticipates FDA clearance as key milestone
  • Revenue forecast: $0.95M in Q1 2025, $2.04M by Q4 2025; XSENCE system soft launch planned for early 2026
Last Updated: 27/03/2025, 15:36
Read Full Transcript

Compare ICCM to Peers and Sector

Metrics to compare
ICCM
Peers
Sector
Relationship
P/E Ratio
−4.2x−3.9x−0.5x
PEG Ratio
−0.44−0.200.00
Price/Book
22.9x2.3x2.6x
Price / LTM Sales
23.7x4.7x3.3x
Upside (Analyst Target)
257.1%32.6%40.3%
Fair Value Upside
Unlock11.7%4.7%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.010
(+261.78% Upside)

Earnings

Latest Release
Aug 13, 2025
EPS / Forecast
0.12 / -0.06
Revenue / Forecast
1.25M / 900.50K
EPS Revisions
Last 90 days

ICCM Income Statement

People Also Watch

61.95
BMNR
+0.51%
15.06
BULL
+0.30%
1.525
INVZ
-3.48%
2.455
OPEN
+1.45%
150.64
CRCL
-1.64%

FAQ

What Stock Exchange Does Icecure Medical Trade On?

Icecure Medical is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Icecure Medical?

The stock symbol for Icecure Medical is "ICCM."

What Is the Icecure Medical Market Cap?

As of today, Icecure Medical market cap is 66.07M.

What Is Icecure Medical's Earnings Per Share (TTM)?

The Icecure Medical EPS (TTM) is -0.28.

When Is the Next Icecure Medical Earnings Date?

Icecure Medical will release its next earnings report on 24 Nov 2025.

From a Technical Analysis Perspective, Is ICCM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Icecure Medical Stock Split?

Icecure Medical has split 0 times.

How Many Employees Does Icecure Medical Have?

Icecure Medical has 65 employees.

What is the current trading status of Icecure Medical (ICCM)?

As of 14 Aug 2025, Icecure Medical (ICCM) is trading at a price of 0.83, with a previous close of 0.84. The stock has fluctuated within a day range of 0.78 to 0.87, while its 52-week range spans from 0.48 to 1.66.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.